Teva to Present at the 2013 Barclays Global Healthcare Conference
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYS: TEVA) will host a live audio webcast at the 2013 Barclays Global Healthcare Conference. Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. will present on Thursday, March 14, 2013.
Teva Presentation at the Barclays Global Healthcare Conference
Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd.
Thursday, March 14,2013 at 9:30 AM (EDT)
Live over the Internet - log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva's website.
Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
Tomer Amitai, 972 (3) 926-7656
Hadar Vismunski-Weinberg, 972 (3) 926-7687
Denise Bradley, 215-591-8974
KEYWORDS: Middle East Israel
The article Teva to Present at the 2013 Barclays Global Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.